Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors - Wikidata - wikimedia - TriplyDB

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

http://www.wikidata.org/entity/Q35800291

about

Targeting DNA Replication Stress for Cancer Therapy Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy Development of cell-cycle checkpoint therapy for solid tumors Targeting the Checkpoint to Kill Cancer Cells Cancer stem cells--important players in tumor therapy resistance Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.Targeting lung cancer through inhibition of checkpoint kinases.Loss of compensatory pro-survival and anti-apoptotic modulator, IKKε, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21.γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments.Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma.Potentiated DNA Damage Response in Circulating Breast Tumor Cells Confers Resistance to Chemotherapy.A novelly synthesized phenanthroline derivative is a promising DNA-damaging anticancer agent inhibiting G1/S checkpoint transition and inducing cell apoptosis in cancer cells.Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase Chemogenetic profiling identifies RAD17 as synthetically lethal with checkpoint kinase inhibition.Overview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes.Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.LKB1 Tumor Suppressor: Therapeutic Opportunities Knock when LKB1 Is Inactivated.Personalised Medicine: Genome Maintenance Lessons Learned from Studies in Yeast as a Model Organism.DNA replication stress and cancer: cause or cure?Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors.Cell Cycle Regulation and Melanoma.Targeting the ATR-CHK1 Axis in Cancer Therapy Targeting Programmed Cell Death Using Small-Molecule Compounds to Improve Potential Cancer Therapy.Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma.HPLC-UV method for simultaneous determination of MK-1775 and AZD-7762 in both acetonitrile-aqueous solution and mouse plasma.Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.CHK it out! Blocking WEE kinase routs TP53 mutant cancer.Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity.Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.ATR/CHK1 inhibitors and cancer therapy.Directing the use of DDR kinase inhibitors in cancer treatment.

P2860

Q26739923-FEA0A022-258F-4F19-9420-4EBA88139058 Q26745686-A722505B-1CB2-46E4-88B1-AD845BDBBD94 Q26781187-604943DE-D7D8-4D85-8042-098B6258076C Q26795781-1F7D5BCC-5A4E-46FE-8655-BC08CEA92886 Q26823015-6E175373-CE06-435E-BA95-3C0F84B54ACB Q28066320-7FAA5BDB-343E-4792-A909-B589506355D0 Q28078268-6B126864-270E-40BA-9957-90CBFC619E8B Q33431248-451B3FA9-8D30-4C41-90B8-18622B575BBB Q33439342-1E218CD4-B7CC-4866-88CA-F1B3AEA63453 Q35128547-2712BEFB-4840-4BCC-986A-6C21FC0559AB Q35149603-5E64FF24-B9DD-4742-9F04-0F51688C8C1B Q35201518-3AFDDDA8-3F1B-4353-8775-2B5869A47269 Q35444029-E40CBE40-8F8F-428D-9000-3DE6E1E63FB3 Q35657004-26D328B2-6781-4F4B-ABA2-79BF833B343E Q35721595-1E388C4F-2D5B-4A07-94DE-C1E916F95A63 Q35847932-3DB983E7-4894-41CF-AEEB-DA7F50AF8A32 Q36075291-DB120C21-F890-4F6B-9122-1A9ECC95525A Q36546455-C65CF1DB-F096-4CF8-870A-A4062ADA9215 Q36784065-B8B70331-C4A9-4BD6-802D-18FB119D83EE Q36838392-711C78FD-FD05-45F9-9D39-1A70E44FB2D0 Q37555069-26D3DCAF-7224-4F52-AAF6-F3F73834E3B3 Q37698312-CFA8D590-C44D-47D6-9B10-7A0A1316B1D4 Q38354509-49384F68-52F9-4DDA-8118-FE195C4F9FA5 Q38608688-C5BCFAA0-0B88-4B5C-9F3A-5326733A8F69 Q38652528-687D3292-0DC2-4575-B38C-B0087931202E Q38660811-6AACD690-064D-456F-87B0-A6020E41B923 Q38815527-CAF30D95-B8CB-4BDD-B5C3-7E9F5B95296F Q38817102-95F9CAB2-E2F6-4937-A1B1-04AF933B8566 Q38881119-1A56F33A-F6BE-4818-ADD9-2BCB16DAD98A Q38901610-B9F717FB-5288-42A1-8CB6-7CC128882048 Q39020753-88A3B488-B162-4887-95C9-50FACDD8BAC0 Q39540757-FBAF75FC-1D68-4F95-B5D8-5CD7AFEA28F5 Q39650689-A3DEA511-9811-47C5-94B4-315190172FBF Q40063670-9272DB44-61F2-4274-B500-AF34B6C107C4 Q41181294-768EA320-D8BB-4898-A8C8-6AF0BD73D09D Q41342704-C33D7DAA-AE0C-4A19-AEB4-17E565F709F7 Q41838038-7E9DD9D5-FA61-49B3-9000-5111AFA6E19D Q47130816-29C05A0C-7E9C-4F48-90C1-EA148CA1B178 Q47622968-04E43A1F-7FF0-4106-9F56-E0470411A9BB Q47687840-074849FB-0C18-4E61-9274-1A77E71A0412

P2860

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

http://www.wikidata.org/entity/Q35800291

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Phase I dose-escalation study ...... nts with advanced solid tumors

@ast

Phase I dose-escalation study ...... nts with advanced solid tumors

@en

type

label

Phase I dose-escalation study ...... nts with advanced solid tumors

@ast

Phase I dose-escalation study ...... nts with advanced solid tumors

@en

prefLabel

Phase I dose-escalation study ...... nts with advanced solid tumors

@ast

Phase I dose-escalation study ...... nts with advanced solid tumors

@en

P1433

Q35800291-696D5738-4765-4CC7-8EAA-54880A77401C

P1476

Q35800291-9C949F89-DD81-417D-AB8B-27E522D5DB5B

P2093

Q35800291-070E40CA-FE1A-4865-828B-301A0CC77880

Q35800291-0EB67714-A985-4052-95DE-32AB331B6C96

Q35800291-259B950B-825E-4A94-A42B-4D7454B64AF8

Q35800291-4D0940FA-3A79-41B2-9501-9C6F0C46CCF9

Q35800291-521D4192-8BF6-4C53-B116-053900DA7D3A

Q35800291-544E8C49-4214-494F-A827-FFE94D14984F

Q35800291-61429393-FC3F-4219-9987-22B33D44775C

Q35800291-614854A9-B67D-419A-9D6E-37295382D48C

Q35800291-7BA4D352-1820-47FE-82D7-4A6EE92106CC

Q35800291-A2C7C6B7-2D25-4748-8E00-6AE23B10A9EB

P2860

Q35800291-0397E468-FAA6-4E43-8937-B7428992A6AB

Q35800291-0FC78DCE-4B96-4A93-BF31-2659F6C8A7D2

Q35800291-1FA4F288-8950-4CF9-B1E1-6C23195D9094

Q35800291-3860E600-778E-447F-9C2B-F8993D4ED8F2

Q35800291-499A838A-B7DF-477C-94FA-4688282E3C58

Q35800291-4F04D67B-6BAC-4067-8C2D-7F88D6B5100C

Q35800291-72720FBE-22CE-4FBF-8A3D-3AC17E7A8EAD

Q35800291-803E1050-C731-42CE-BB2F-7DA14E4B8977

Q35800291-8BD087C3-ACFF-4EDB-BDBF-9BCD79434AB0

Q35800291-9A1E4026-6050-4E3B-89E2-90CE98E6D936

P2888

Q35800291-0AB988CB-690D-4085-8C3A-950E0736F93B

P304

Q35800291-15019E08-0BBE-4E98-AF61-B42078298338

P31

Q35800291-46FB8911-951B-4D38-8B2D-05559A7456B6

P356

Q35800291-0AD83E9E-4600-4BCB-ABB3-F5E813CECD47

P433

Q35800291-88D58E94-4210-41A1-BCE3-96819540E397

P478

Q35800291-D56892DD-95E6-484A-97CA-28D96994B1A4

P577

Q35800291-9DAA42DC-305F-4218-A5AC-D079B93AFAD0

P698

Q35800291-AF56404F-7F4F-46B3-9D87-166549235BCA

P932

Q35800291-AEFDE095-A689-47FC-9D05-C4D1965D9E8B

P356

S00280-014-2380-5

P1433

Cancer Chemotherapy and Pharmacology

P1476

Phase I dose-escalation study ...... nts with advanced solid tumors

@en

P2093

Adrian Senderowicz

http://www.w3.org/2001/XMLSchema#string

David Cosgrove

http://www.w3.org/2001/XMLSchema#string

Edward Sausville

http://www.w3.org/2001/XMLSchema#string

Felix Agbo

http://www.w3.org/2001/XMLSchema#string

Judith Carter

http://www.w3.org/2001/XMLSchema#string

Lisa Malburg

http://www.w3.org/2001/XMLSchema#string

Mary F Quinn

http://www.w3.org/2001/XMLSchema#string

Michael Carducci

http://www.w3.org/2001/XMLSchema#string

Nilofer Azad

http://www.w3.org/2001/XMLSchema#string

Patricia Lorusso

http://www.w3.org/2001/XMLSchema#string

P2860

Structural basis for Chk1 inhibition by UCN-01

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Checkpoints: controls that ensure the order of cell cycle events

The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01

Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice

Cell cycle checkpoint signaling through the ATM and ATR kinases

The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae

Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours.

In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762.

Anticancer drug targets: cell cycle and checkpoint control.

P2888

s00280-014-2380-5

P304

539-549

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-014-2380-5

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24448638

http://www.w3.org/2001/XMLSchema#string

P932

4486055

http://www.w3.org/2001/XMLSchema#string